Mack Roach III, MD

Professor and Chair, Department of Radiation Oncology, and Professor, Department of Urology, UCSF

Phone: (415) 353-9807 (appts)
Box 1708, UCSF
San Francisco, CA 94143-1708

View on UCSF Profiles

Read More About Mack Roach III

Artist’s Heart Guides Treatment Plans

Interest in art and physics fuels drive to improve radiation therapy.

Meet more of Our Heroes »

Additional Websites

• Physician Referral Directory

Education

Morehouse College, Atlanta, GA, BS, 1975, Physics
Stanford University School of Medicine, Stanford,CA, MD, 1979, Medicine
University of California San Francisco, Fellow, 1981-83, Med Oncology
Stanford University School of Medicine, Stanford,CA, Resident, 1984-87, Radiation Oncology

Professional Experience

• 1987-1988
  Acting Chief, Radiation Oncology Service, VA Medical Center, Martinez, CA
• 1988-1990
  Chief, Radiation Oncology Service, VA Medical Center, Martinez, CA
• 1990-1994
  Assistant Professor, Department of Radiation Oncology, UCSF
• 1994-2000
  Associate Professor, Department of Radiation Oncology, UCSF
• 2000-present
  Professor, Department of Radiation Oncology & Urology, UCSF
• 2003-2007
  Vice Chair, Department of Radiation Oncology, UCSF
• 2006-2007
  Interim Chair, Department of Radiation Oncology
• 2007-present
  Chair, Department of Radiation Oncology

Honors & Awards

• 1980-1981
  Outstanding Intern of the Year (Charles R. Drew Award)
• 1981-1982
  Fellow of the American Cancer Society
• 1994
  UCSF Health Net Wellness Award
• 1994-1997
  American Cancer Society Career Development Award
• 1996-97; 1997-98; 2001-02
  "The Best Doctors in America"
• 2002
  Fellow, American College of Radiology
• 2002-05
  President, John Hale Medical Society
• 2005
  10 Most Influential African Americans in the Bay Area (Healthcare)

Selected Publications

1. Chen CP, Weinberg V, Shinohara K, Roach M, Nash M, Gottschalk A, Chang AJ, Hsu IC. Salvage HDR Brachytherapy for Recurrent Prostate Cancer After Previous Definitive Radiation Therapy: 5-Year Outcomes. Int J Radiat Oncol Biol Phys. 2013 Jun 1; 86(2):324-9.
   View on PubMed
2. Mohler JL, Armstrong AJ, Bahnson RR, Boston B, Busby JE, D'Amico AV, Eastham JA, Enke CA, Farrington T, Higano CS, Horwitz EM, Kantoff PW, Kawachi MH, Kuettel M, Lee RJ, MacVicar GR, Malcolm AW, Miller D, Plimack ER, Pow-Sang JM, Roach M, Rohren E, Rosenfeld S, Srinivas S, Strope SA, Tward J, Twardowski P, Walsh PC, Ho M, Shead DA. Prostate cancer, Version 3.2012: featured updates to the NCCN guidelines. J Natl Compr Canc Netw. 2012 Sep; 10(9):1081-7.
   View on PubMed
3. Michalski J, Winter K, Roach M, Markoe A, Sandler HM, Ryu J, Parliament M, Purdy JA, Valicenti RK, Cox JD. Clinical outcome of patients treated with 3D conformal radiation therapy (3D-CRT) for prostate cancer on RTOG 9406. Int J Radiat Oncol Biol Phys. 2012 Jul 1; 83(3):e363-70.
   View on PubMed
4. Créhange G, Chen CP, Hsu CC, Kased N, Coakley FV, Kurhanewicz J, Roach M. Management of prostate cancer patients with lymph node involvement: a rapidly evolving paradigm. Cancer Treat Rev. 2012 Dec; 38(8):956-67.
   View on PubMed
5. Hsu CC, Hsu H, Pickett B, Crehange G, Hsu IC, Dea R, Weinberg V, Gottschalk AR, Kurhanewicz J, Shinohara K, Roach M. Feasibility of MR Imaging/MR Spectroscopy-Planned Focal Partial Salvage Permanent Prostate Implant (PPI) for Localized Recurrence After Initial PPI for Prostate Cancer. Int J Radiat Oncol Biol Phys. 2013 Feb 1; 85(2):370-7.
   View on PubMed
6. Meijer HJ, Debats OA, Roach M, Span PN, Witjes JA, Kaanders JH, van Lin EN, Barentsz JO. Magnetic resonance lymphography findings in patients with biochemical recurrence after prostatectomy and the relation with the stephenson nomogram. Int J Radiat Oncol Biol Phys. 2012 Dec 1; 84(5):1186-91.
   View on PubMed
7. Chang AJ, Roach M. Radium-223: down to the bone, and less is more. Oncology (Williston Park). 2012 Apr; 26(4):342, 344.
   View on PubMed
8. Bastian PJ, Boorjian SA, Bossi A, Briganti A, Heidenreich A, Freedland SJ, Montorsi F, Roach M, Schröder F, van Poppel H, Stief CG, Stephenson AJ, Zelefsky MJ. High-risk prostate cancer: from definition to contemporary management. Eur Urol. 2012 Jun; 61(6):1096-106.
   View on PubMed
9. Roach M. Long-term potency preservation following brachytherapy for prostate cancer. BJU Int. 2012 Jul; 110(2):225.
   View on PubMed
10. Arrayeh E, Westphalen AC, Kurhanewicz J, Roach M, Jung AJ, Carroll PR, Coakley FV. Does local recurrence of prostate cancer after radiation therapy occur at the site of primary tumor? Results of a longitudinal MRI and MRSI study. Int J Radiat Oncol Biol Phys. 2012 Apr 1; 82(5):e787-93.
    View on PubMed
11. Grimm P, Billiet I, Bostwick D, Dicker AP, Frank S, Immerzeel J, Keyes M, Kupelian P, Lee WR, Machtens S, Mayadev J, Moran BJ, Merrick G, Millar J, Roach M, Stock R, Shinohara K, Scholz M, Weber E, Zietman A, Zelefsky M, Wong J, Wentworth S, Vera R, Langley S. Comparative analysis of prostate-specific antigen free survival outcomes for patients with low, intermediate and high risk prostate cancer treatment by radical therapy. Results from the Prostate Cancer Results Study Group. BJU Int. 2012 Feb; 109 Suppl 1:22-9.
    View on PubMed
12. Hwang AB, Chen J, Nguyen TB, Gottschalk AG, Roach MR, Pouliot J. Irradiation of the prostate and pelvic lymph nodes with an adaptive algorithm. Med Phys. 2012 Feb; 39(2):1119-24.
    View on PubMed
13. Myrehaug S, Chan G, Craig T, Weinberg V, Cheng C, Roach M, Cheung P, Sahgal A. A treatment planning and acute toxicity comparison of two pelvic nodal volume delineation techniques and delivery comparison of intensity-modulated radiotherapy versus volumetric modulated arc therapy for hypofractionated high-risk prostate cancer radiotherapy. Int J Radiat Oncol Biol Phys. 2012 Mar 15; 82(4):e657-62.
    View on PubMed
14. Roach M, Thomas K. Overview of randomized controlled treatment trials for clinically localized prostate cancer: implications for active surveillance and the United States preventative task force report on screening? J Natl Cancer Inst Monogr. 2012; 2012(45):221-9.
    View on PubMed
15. Roach M. Editorial comment. Urology. 2011 Dec; 78(6):1367-8.
    View on PubMed
16. Shiao SL, Sahgal A, Hu W, Jabbari S, Chuang C, Descovich M, Hsu IC, Gottschalk AR, Roach M, Ma L. Temporal compartmental dosing effects for robotic prostate stereotactic body radiotherapy. Phys Med Biol. 2011 Dec 21; 56(24):7767-75.
    View on PubMed
17. Moul JW, Evans CP, Gomella LG, Roach M, Dreicer R. Traditional approaches to androgen deprivation therapy. Urology. 2011 Nov; 78(5 Suppl):S485-93.
    View on PubMed
18. Moul JW, Kibel AS, Roach M, Dreicer R. Indications and practice with androgen deprivation therapy. Urology. 2011 Nov; 78(5 Suppl):S478-81.
    View on PubMed
19. Stephenson AJ, Bolla M, Briganti A, Cozzarini C, Moul JW, Roach M, van Poppel H, Zietman A. Postoperative radiation therapy for pathologically advanced prostate cancer after radical prostatectomy. Eur Urol. 2012 Mar; 61(3):443-51.
    View on PubMed
20. Cunha JA, Pouliot J, Weinberg V, Wang-Chesebro A, Roach M, Hsu IC. Urethra low-dose tunnels: validation of and class solution for generating urethra-sparing dose plans using inverse planning simulated annealing for prostate high-dose-rate brachytherapy. Brachytherapy. 2012 Sep-Oct; 11(5):348-53.
    View on PubMed

View on UCSF Profiles